Xeris Biopharma reported a record-setting Q3 2025 with total product revenue surpassing $74 million, reflecting a 40% year-over-year increase, driven primarily by exceptional growth in its flagship product, RECORLEV.

• RECORLEV revenue exceeded $37 million, representing a 109% year-over-year growth, supported by a 108% increase in the average number of patients on therapy.
• Total revenue guidance for 2025 has been revised upward to $285-290 million, marking a projected 42% increase at the midpoint.
• Gvoke and KEVEYIS achieved revenues of $25.2 million and $11.9 million, respectively, highlighting steady growth and an expanding patient base.
• The company generated positive cash flow and net income for the first time, showcasing financial scalability and operational strength.
• Strategic expansion initiative underway, nearly doubling sales and patient support teams, aiming to enhance reach and capitalize on market opportunities.